A detailed history of Ubs Oconnor LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 65,940 shares of ITOS stock, worth $557,852. This represents 0.05% of its overall portfolio holdings.

Number of Shares
65,940
Holding current value
$557,852
% of portfolio
0.05%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.09 - $17.97 $308,925 - $550,187
30,617 Added 86.68%
65,940 $673,000
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $364,886 - $638,993
35,323 New
35,323 $524,000
Q3 2023

Nov 14, 2023

BUY
$10.95 - $14.6 $87,600 - $116,800
8,000 Added 15.45%
59,764 $654,000
Q2 2023

Aug 14, 2023

BUY
$12.93 - $18.05 $669,308 - $934,340
51,764 New
51,764 $685 Million
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $95,046 - $165,126
7,300 Added 11.77%
69,300 $943,000
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $79,965 - $97,200
4,500 Added 7.83%
62,000 $0
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $93,000 - $136,250
5,000 Added 9.52%
57,500 $1.1 Billion
Q2 2022

Aug 12, 2022

BUY
$16.57 - $35.1 $124,275 - $263,250
7,500 Added 16.67%
52,500 $0
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $1.44 Million - $2.14 Million
45,000 New
45,000 $0

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $301M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.